Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A. s. Wright
Vascular device practices in extremely preterm infants: an international cross-sectional survey
Abstract To explore global practices in vascular device selection, securement, and monitoring for extremely preterm infants, and to assess regional variation. A web-based cross-sectional survey was completed by one respondent per neonatal unit. We received 848 responses from 100 countries. Guideline availability varied: 85–98% for umbilical venous catheters (UVCs) and 29–97% for peripheral intravenous catheters.
Incidence of pre-eclampsia in triplet pregnancies with and without embryo reduction
INTRODUCTION Pre-eclampsia (PE) is a leading global cause of maternal and perinatal mortality and morbidity1. In singleton pregnancies, the incidence of PE is 3–5%, and in twin pregnancies, the risk is three times higher for overall PE and nine times higher for preterm PE (PE with delivery < 37 weeks' gestation)2. There is a sparsity of data for PE in triplet pregnancies. The best method for assessing the risk of development of PE is the competing-risks model3.
Re: Fetal biometry reference ranges derived from prospective twin population and evaluation of adverse perinatal outcome
Linked article: This Correspondence comments on Dicker et al. Click here to view the article. Linked article: Click here to see the Reply to this Correspondence.
Screening for pre‐eclampsia using pregnancy‐associated plasma protein‐A or placental growth factor measurements in blood samples collected at 8-14 weeks' gestation - Rode - Ultrasound in Obstetrics & Gynecology - Wiley Online Library
INTRODUCTION Blood sampling for combined first-trimester aneuploidy screening (cFTS) can be conducted from 8 weeks' gestation1-3, whereas the first-trimester scan must be performed at 11–14 weeks4. The best performance of cFTS, including measurement of pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG), is obtained when blood is collected before 11 weeks3, 5-8.
Validation of Fetal Medicine Foundation charts for fetal growth in twins: nationwide Danish cohort study
What are the novel findings of this work? This study used a nationwide Danish cohort of 8542 dichorionic and 1675 monochorionic diamniotic twin pregnancies to externally validate the Fetal Medicine Foundation (FMF) chorionicity-specific models for fetal growth in twin pregnancies compared with singleton percentiles. The dual-percentile scale may offer improved resolution compared with the conventional scale in g. What are the clinical implications of this work?
Fetal Medicine Foundation charts for fetal growth in twins
Supporting Information Filename Description uog27514-sup-0001-Supinfo.docxWord 2007 document , 30.6 KB Appendix S1 uog27514-sup-0002-Figures.pptxPowerPoint 2007 presentation , 168.3 KB Figure S1 Mean singleton z score for DC (red line) and MCDA twins (black line). Figure S2: Distribution of estimated fetal weight z-scores for DC twins delivered at 36 weeks or later at scheduled visits (every four weeks from 20 to 36 weeks).
OC14.07: Performance of the first trimester combined screening of preterm pre‐eclampsia: results from a cohort of 10,110 pregnancies in Spain
Objectives To evaluate the accuracy of the Fetal Medicine Foundation (FMF) triple test, a competing risk model, in predicting preterm pre-eclampsia (PE) in a Spanish cohort. Methods A prospective cohort study was conducted in eight fetal-medicine units in five Spanish regions from September 2017 to December 2019. Pregnant women with singleton pregnancies and non-malformed live fetuses attending their routine ultrasound examination at 11+0 to 13+6 weeks of gestation were included.
Incidence of neonatal morbidity in small‐for‐gestational‐age twins based on singleton and twin charts
Objective To compare morbidity, as measured by length of stay in the neonatal intensive care unit (NICU), in twin and singleton gestations classified as small-for-gestational age (SGA) according to estimated fetal weight < 10th percentile on twin or singleton growth charts. Methods NICU length of stay was compared in 1150 twins and 29 035 singletons that underwent ultrasound assessment between 35 + 0 and 36 + 6 weeks' gestation.
Screening for pre‐eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation
Supporting Information Filename Description uog27481-sup-0001-Tables.docxWord 2007 document , 15.5 KB Table S1 Model to define glycosylated fibronectin multiples of the median values in pregnancies that deliver with pre-eclampsia Table S2 Correlations of log10 multiples of the median values of glycosylated fibronectin with those of other biomarkers of pre-eclampsia REFERENCES 1, , . Preeclampsia. N Engl J Med 2022; 386: 1817–1832. 2, , . The competing risk approach for prediction of preeclampsia.
Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre‐eclampsia in women with chronic hypertension
REFERENCES 1, , , , . Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2017; 50: 228–235. 2, , , , , . Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 2014; 348: g2301. 3, , , , , , . Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks' gestation. Am J Obstet Gynecol 2016; 214: 103. e1–12. 4, , , , , , , , , , , , , , , , , , , .
Ophthalmic artery Doppler at 36 weeks' gestation in prediction of pre‐eclampsia: validation and update of previous model
Supporting Information Filename Description uog27464-sup-0001-FigureS1.pptxPowerPoint 2007 presentation , 77.5 KB Figure S1 Calibration plots for prediction of pre-eclampsia (PE) with delivery within 3 weeks and at any time after assessment at 35 + 0 to 36 + 6 weeks in screening by a combination of maternal factors and peak systolic velocity ratio in validation dataset.
Prediction using serum glycosylated fibronectin of imminent pre‐eclampsia in women with new‐onset hypertension
REFERENCES 1, , . Preeclampsia. N Engl J Med 2022; 386: 1817–1832. 2, , , , , , , , , , , , . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658. 3, , , , , , , , , , , , . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683. 4, , , , , , , , , , , .
Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing‐risks model
REFERENCES 1, , . Preeclampsia. N Engl J Med. 2022; 386: 1817–1832. 2, , . The competing risk approach for prediction of preeclampsia. Am J Obstet Gynecol 2020; 223: 12–23.e7. 3, , , , , , . Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016; 214: 103.e1–12. 4, , , , . Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation. Am J Obstet Gynecol 2019; 220: 197e1–11. 5, , , , , , , , , , , , , , , , , , , .
Management of Impacted Fetal Head at Caesarean Birth (2025 Second Edition)
Identification and Assessment of Evidence (Figures 1-3, Table 1) A targeted search of medical databases (Cochrane Central Register of Controlled Trials [CENTRAL], Cochrane Database of Systematic Reviews, MEDLINE, EMcare, EMBASE and DARE) was undertaken for studies published in English from 1980 to 1 January 2023, comparing various techniques used for managing IFH.
Management of common infections in solid organ transplant recipients in British Columbia
Issue: BCMJ, vol. 64 , No. 4 , May 2022 , Pages 166-173 Clinical Articles ABSTRACT: Solid organ transplantation is becoming increasingly common in British Columbia, and infectious complications in these immunosuppressed patients are being seen with increasing frequency by community providers.
Mepolizumab does not alter the blood basophil count in severe asthma
Letter to the Editor Mepolizumab does not alter the blood basophil count in severe asthma A. Wright Corresponding Author E-mail address: adam.wright@le.ac.uk Department of Respiratory Sciences, University of Leicester, Leicester, UK Corresponding author: Dr Adam Wright, Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, LE3 9QP, UK. Tel: 0044 116 258 3011 E‐mail: adam.wright@le.ac.uk Search for more papers by this author S.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A. s.
Contact A. s., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack